Project Grant R01HL174794
- This $423,000 Project Grant was awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the direct regulation of cell cycle genes by cell identity factors during myeloid differentiation. Specifically, the project aims to determine how transcription factors PU.1 and C/EBP regulate the expression of cyclin-dependent kinase inhibitors and cyclin D2 to induce cell cycle...
- This $445,000 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The Children's Hospital of Philadelphia (CHOP) to investigate how the tropomyosin 1 gene product impacts the development of hematopoietic stem and progenitor cells and their precursors. The goal is to define genetic determinants of hematopoiesis that could enhance in vitro production of blood cells to support research and development of blood...
- This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $489,500 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the use of the compound Repsox for prophylactic intervention in Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) due to RUNX1 haploinsufficiency. The research aims to examine the effects of Repsox on RUNX1 expression, activity, and isoform usage in FPDMM hematopoietic...
- This $178,000 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), aims to develop a bone marrow organoid system to study RUNX1-familial platelet disorder with associated myeloid malignancy (RUNX1-FPD/MM). RUNX1-FPD/MM is a rare genetic disorder that can lead to thrombocytopenia, platelet dysfunction, and a high risk of developing myelodysplastic syndrome and leukemia. The project, awarded to The...
- This Project Grant award of $248,999.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Emory University to investigate the molecular mechanisms underlying the context-specific functions of RUNX transcription factors in directing hematopoietic (blood) cell identity. The research aims to determine how RUNX factors dynamically regulate distinct gene programs during early T cell development and megakaryocyte differentiation, as...
- This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $146,922.00 to the Albert Einstein College of Medicine to investigate genotype-environment interactions that drive dysfunction in hematopoietic stem and progenitor cells (HSPCs). The research aims to decipher how HSPC dysregulation, a major driver of myeloid malignancies like myelodysplastic syndromes (MDS), is influenced by the interplay between genetic...
- The National Heart, Lung, and Blood Institute, through the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $697,296 project grant to The Trustees of Columbia University in the City of New York, Health Sciences Division, to investigate the role of N6-methyladenosine (m6A) epitranscriptomic mRNA modification in the generation and regeneration of the hematopoietic stem cell (HSC) niche within the bone marrow. This 4-year project aims to characterize how m6A regulates the...
- This $517,090 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Beckman Research Institute of the City of Hope supports innovative research aimed at understanding the role and function of a novel gene, A978, which is overexpressed in Philadelphia chromosome-positive and Philadelphia-like B-cell acute lymphoblastic leukemia (B-ALL). The key objectives of this 5-year project are to: 1) determine the biological effects of A978 in...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $461,132 to the University of Illinois to determine the mechanisms by which myeloid-derived suppressor cells (MDSCs) can promote the recovery of the bone marrow endothelial niche after chemotherapy and radiation treatment. The key objectives are to: 1) investigate how Jagged1-expressing pro-MDSCs enhance hematopoietic recovery after preconditioning, 2)...
TRANSCRIPTIONAL REGULATION OF MYELOPOIESIS - ABSTRACT MYELOID CELLS ARE AMONGST THE FIRST RESPONDERS TO PATHOGENIC INSULTS, BUT THERE REMAINS A SUBSTANTIAL KNOWLEDGE GAP CONCERNING MECHANISMS THAT CONTROL THEIR DEVELOPMENT IN THE BONE MARROW (BM). WE HAVE FOUND THAT THE TRANSCRIPTION FACTOR THPOK (T-HELPER-INDUCING POZ-KRUPPEL FACTOR) PLAYS A CRITICAL UNEXPECTED ROLE IN MYELOID LINEAGE DIFFERENTIATION, AS THPOK NULL MICE SHOW EXPANSION OF NEUTROPHIL PROGENITORS AND PRECURSORS IN THE BM, LEADING TO NEUTROPHILIA AND PROTECTION AGAINST SEPSIS. LOSS OF THPOK EXPRESSION CAUSES WIDESPREAD TRANSCRIPTIONAL REPROGRAMMING THROUGHOUT MYELOPOIESIS. HERE, WE PROPOSE TO TEST THE HYPOTHESIS THAT THPOK SERVES AS A TRANSCRIPTIONAL CHECKPOINT FOR NEUTROPHIL COMMITMENT AND GRANULOCYTE LINEAGE OUTPUT IN 3 SPECIFIC AIMS. AIM 1 WILL DEFINE HOW GROWTH FACTOR (GF)/CYTOKINE RECEPTOR SIGNALING REGULATES THPOK EXPRESSION IN MYELOID PROGENITORS. THE UPSTREAM FACTORS THAT CONTROL THPOK INDUCTION DURING MYELOPOIESIS ARE NOT KNOWN BUT ARE LIKELY TO INCLUDE BM-DERIVED GF / CYTOKINE(S), WHICH ARE KNOWN TO DIRECT MYELOID LINEAGE CHOICE. HERE WE WILL DEFINE THE SIGNALING CASCADE/S FROM GF/CYTOKINE RECEPTOR TO THPOK TRANSCRIPTIONAL CIS ELEMENT THAT CONTROL THPOK INDUCTION AT EACH SPECIFICATION STEP. WE WILL USE IN VITRO HEMATOPOIETIC PROGENITOR CULTURES, AN EXISTING PANEL OF KNOCK-IN MOUSE MODELS HARBORING MUTATIONS IN THE THPOK CIS ELEMENTS TO DELINEATE THE UPSTREAM PATHWAYS THAT DRIVE THPOK EXPRESSION DURING MYELOPOIESIS. AIM 2 WILL ELUCIDATE THE MODUS OPERANDI BY WHICH THPOK REGULATES GENE EXPRESSION DURING MYELOPOIESIS. THE MECHANISM BY WHICH THPOK REGULATES MYELOPOIESIS REMAIN LARGELY UNCLEAR. WE PROPOSE THAT THPOK ACTS IN PART BY RECRUITING CO- FACTORS TO MODULATE CHROMATIN ACCESSIBILITY, INCLUDING THE NURD COMPLEX. WE HAVE GENERATED 3 DIFFERENT THPOK AND 2 GFI1 MUTANT MOUSE MODELS THAT ALTER THEIR ABILITY TO INTERACT WITH COFACTORS OR WITH DNA BINDING SITES. USING MYELOID AND GRANULOCYTE PROGENITORS FROM THESE MUTANT MICE, CHROMATIN ACCESSIBILITY ASSAY, CHIP SEQ, AND RNASEQ WE WILL DETERMINE THE FUNCTIONAL OUTCOMES OF THPOK AND GFI1 INTERACTION ON MYELOPOIESIS. AIM 3 WILL TEST THE HYPOTHESIS THAT THPOK IS A CRITICAL REGULATOR OF INFECTION-INDUCED EMERGENCY MYELOPOIESIS. EMERGENCY MYELOPOIESIS IS CRITICAL FOR ENHANCED RELEASE OF NEUTROPHILS AND MONOCYTES FROM THE BM DURING INFECTION, BUT THE UNDERLYING REGULATION REMAINS POORLY UNDERSTOOD. OUR PRELIMINARY DATA SUGGEST A ROLE FOR THPOK. USING OUR ESTABLISHED THPOK LOSS- AND GAIN-OF-FUNCTION MOUSE MODELS, WE WILL EXAMINE THE FUNCTIONAL CONSEQUENCES OF THPOK-MEDIATED GENE REGULATION ON LPS AND GCSF-MEDIATED EMERGENCY MYELOPOIESIS. THIS PROPOSAL REPRESENTS THE FIRST STUDY TO DISSECT THE ROLE OF THPOK IN MYELOID DEVELOPMENT AND FUNCTION, AND IF SUCCESSFUL WILL REPRESENT AN IMPORTANT ADVANCE IN THE FIELD. THE PROPOSED STUDIES WILL ULTIMATELY ALLOW DEVELOPMENT OF NOVEL TREATMENT STRATEGIES TO REPROGRAM MYELOPOIESIS UNDER DIFFERENT PATHOLOGICAL CONDITIONS SUCH AS NEUTROPENIA, SEPSIS, AND MYELOPROLIFERATIVE DISORDER THROUGH TARGETING OF THPOK AND ITS ASSOCIATED PATHWAYS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($306k) | 4/25/25 | ||
| Not listed | $0 | 4/7/25 | ||
| Not listed | $0 | 4/7/25 | ||
| Not listed | $421.8k | 7/10/24 | ||
| Not listed | $421.8k | 7/10/24 |